Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03152500
Other study ID # NL58195.068.16
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2017
Est. completion date October 30, 2017

Study information

Verified date May 2017
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study the investigators will investigate the stability of lens position and the visual outcome after implantation of the new FEMTIS-IOL using FLACS capsulotomy compared to conventional placement of the IOL in the capsular bag. So far, there are no published studies using the FEMTIS-IOL. Therefore, the investigators will perform this randomized control trial.


Description:

Cataract is a clouding of the crystalline lens which causes vision loss and blindness if untreated. Cataract surgery is the most frequently performed surgical intervention in medicine with an incidence of 880 surgeries per 100.000 population in 2010 amounting to a total number of over 160.000 surgeries per year in the Netherlands.1,3 The number of individuals with cataracts is predicted to reach 30 million by the year 2020.2 Due to aging of the general population this number of cataracts will only grow in the future.

For the last decade conventional phacoemulsification cataract surgery (CPCS) is the dominant form of cataract surgery in developed countries, accounting for over 90 percent of these procedures.4 The basic phacoemulsification procedure has remained largely unchanged over the past 20 years, including a series of steps: creating corneal incision, capsulorhexis and lensfragmentation.4 Although highly successful, each of the steps mentioned above are created manually which affects the safety and effectiveness of the procedure.

Since the first human eye was treated by femtosecond laser cataract surgery in 2008, the femtosecond-laser assisted cataract surgery (FLACS) became an innovative growing new technology in the world of cataract surgery.4-7 Femtosecond-lasers are capable of performing some of the most delicate and essential key steps during cataract surgery: capsulotomy, lens fragmentation, and corneal incisions. 'Automating' these steps and performing them with increased precision could lead to an improved quality of capsulotomy, easier lens fragmentation, and more precisely positioned corneal incisions, which in turn, lead to improved visual and refractive outcomes, a decrease in intra- and postoperative complication rates, and increased quality of life.

In order to remove the crystallized human lens, a circular opening in the capsular lens bag, capsulotomy, needs to be created. After removing the lens an intraocular lens (IOL) can be inserted in the empty capsule bag. However, one of the factors affecting postoperative achieved visual acuity and refraction, is the behaviour of this IOL in the capsular bag. Preoperative measurements need to be obtained in order to calculate the required IOL. One of the challenges of these IOL calculations is determining exactly where in the eye the IOL will end up, the effective lens position (ELP). The position of the IOL is crucial for the IOL's general performance because it influences the postoperative IOL tilt, decentration, and posterior capsule opacification (PCO). Considering the anatomical variety between patients, the predictability of an individual's ELP remains an educated guess.

The ELP, and therefore the amount of IOL tilt, decentration and PCO, of an IOL is mainly influenced by the interaction between the IOL and the lens capsule, especially during the time of capsule shrinkage. Theoretically, the positive optical effect of an IOL is lost when there is more than 7 degrees of tilt or more than 0.4 mm of decentration.8 Furthermore, studies have shown the effect of axial displacement of an IOL on refractive error. There is approximately 1.25 D change per millimetre of the IOL's longitudinal displacement.9 This reflects the importance of a stable and predictable ELP.

As mentioned above, the anatomy of an individual's eye is unique and therefore, each ELP will be different when placing the IOL in the capsular bag. Therefore, a new lens type has been developed: the FEMTIS® FB-313 laser lens (FEMTIS-IOL, Oculentis). This IOL has a special haptic system and is designed to be clasped in the capsular bag opening and therefore, the ELP of this IOL is theoretically more stable and predictable, resulting in a higher predictability of refractive and visual outcomes. However, in order to provide as much stability as possible a (nearly) perfect capsulotomy is needed. Several comparative studies have shown that femtosecond-lasers produce a more precise, circular, reproducible, and better centered capsulotomy compared to conventional manual capsulorhexis.6-7 The combination between the femtosecond-assisted capsulotomy and the implantation of a FEMTIS-IOL in the capsular opening, could definitely contribute to the search of perfection in cataract surgery.

In this study the investigators will investigate the stability of lens position and the visual outcome after implantation of the new FEMTIS-IOL using FLACS capsulotomy compared to conventional placement of the IOL in the capsular bag. So far, there are no published studies using the FEMTIS-IOL. Therefore, the investigators will perform this randomized control trial.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date October 30, 2017
Est. primary completion date September 30, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria:

- Minimum 40 years of age

- Cataracta Senilis

- Expected postoperative astigmatism = 0.75 D (combination with FLACS AK is tolerated up to 1.25 D preoperative astigmatism)

- IOL power calculation between +10.00 D and 27.00 D

- Expected postoperative best-corrected visual acuity of logMAR +0.3 or better

- If eligible, availability to undergo second eye surgery within 2 weeks of the first eye surgery

- Willing and able to comply with scheduled visits and other study procedures

- Signed informed consent.

Exclusion Criteria:

- Traumatic cataract

- Previous corneal surgery and/or reshaping

- Clinically significant corneal endothelial dystrophy (e.g., Fuchs' dystrophy)

- Irregular astigmatism

- History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.)

- Extensive age related macular degeneration (atrophic or exudative age-related macular degeneration or numerous soft drusen)

- Extensive visual field loss (e.g., glaucoma, history of cerebral vascular accidents, etc.)

- Extensive diabetic macular disease

- Amblyopia, strabismus

- Keratoconus

- Pseudoexfoliation syndrome or other capsule or zonular abnormalities that could affect postoperative centration or tilt of the IOL

- Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions)

- Cognitive, cerebral or concentration disorders (e.g. dementia, Parkinson, etc.)

- Suturing of incision required at time of surgery

- Complications during surgery of the first eye.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
FEMTIS 313G IOL
Haptic design that enclaves the capsulorrhexis
Acrysof SN60WF IOL
IOL in the bag

Locations

Country Name City State
Netherlands Maastricht University Medical Centre Maastricht Limburg

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Medical Center Oculentis

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Decentration:To compare the amount of decentration between FEMTIS IOL versus a standard monofocal IOL (Acrysof monofocal IOL) using retro-illumination slitlamp photographs To compare the amount of decentration between FEMTIS IOL versus a standard monofocal IOL (Acrysof monofocal IOL) using retro-illumination slitlamp photographs 13 weeks/3months
Secondary Rotation stability To compare rotation stability between both IOls using retro-illumination slitlamp photographs 13 weeks/3months
Secondary Tilt: To compare the amount of tilt between both IOls using Scheimpflug images To compare the amount of tilt between both IOls using Scheimpflug images 13 weeks/3months
Secondary Visual outcomes Uncorrected (UDVA) and corrected (CDVA) distance visual acuity using ETDRS reading charts. 13 weeks/3months
See also
  Status Clinical Trial Phase
Completed NCT04685538 - Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification. Phase 3
Recruiting NCT06060041 - IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting NCT05518539 - Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Recruiting NCT05271942 - Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods N/A
Active, not recruiting NCT04778501 - PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia N/A
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT03751033 - Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings N/A
Completed NCT02529488 - Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00 N/A
Completed NCT04539548 - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract Phase 3
Completed NCT03740659 - Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery Phase 2
Completed NCT03494257 - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification N/A
Completed NCT05119127 - Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome. N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT03739528 - Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery Phase 3
Completed NCT02888210 - A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery Phase 3
Completed NCT03356847 - Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery N/A
Completed NCT04332640 - Clinical Evaluation of the Next Generation Phaco System N/A
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT03050697 - Evaluation of the Safety and Performance of the HARMONI® Toric Lens N/A